X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will advance the development of DB107 which consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug, for high–grade glioma including glioblastoma.
Lead Product(s): Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area: Oncology Product Name: DB107-RRV
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine
Deal Size: $11.8 million Upfront Cash: Undisclosed
Deal Type: Funding April 30, 2024
Details:
DB104 (liafensine) is a first–in–class triple reuptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine. It is being evaluated for the treatment of patients with treatment-resistant depression.
Lead Product(s): Liafensine
Therapeutic Area: Psychiatry/Psychology Product Name: DB104
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
DB107 (vocimagene amiretrorepvec) is a two-part cancer-selective immunotherapy comprising an investigational gene therapy treatment and an investigational small molecule, which is investigated for the treatment of newly diagnosed high grade glioma.
Lead Product(s): Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area: Oncology Product Name: DB107
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.
Lead Product(s): Liafensine
Therapeutic Area: Psychiatry/Psychology Product Name: DB104
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Curia
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
Under the agreement, QIAGEN will develop a diagnostic assay that can detect the Denovo Genomic Marker 1 (DGM1) in DLBCL patients, a biomarker discovered by Denovo that predicts the responsiveness to DB102, also known as enzastaurin.
Lead Product(s): Enzastaurin,Rituximab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Kinenza
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Qiagen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 09, 2021
Details:
Lundbeck gets options to re-acquire idalopirdine for predetermined undisclosed financial terms, with Denovo and Lundbeck sharing China rights in the event Lundbeck's options are exercised and Denovo retaining all global rights in the event Lundbeck's options are not exercised.
Lead Product(s): Idalopirdine
Therapeutic Area: Neurology Product Name: DB109
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: H. Lundbeck AS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 01, 2021
Details:
Aytu BioPharma has acquired substantially all the assets of Rumpus Therapeutics, including Rumpus' option to license DB102 for rare genetic pediatric onset or congenital disorders outside of oncology from Denovo Biopharma LLC.
Lead Product(s): Enzastaurin
Therapeutic Area: Genetic Disease Product Name: DB102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aytu BioScience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 13, 2021
Details:
DB108 is a recombinant protein drug that inhibits tumor growth and metastasis by inhibiting angiogenesis. Denovo gains global rights (except China) to develop, manufacture and commercialize endostatin from Jiangsu Wuzhong Pharmaceutical Group Corporation.
Lead Product(s): Endostatin
Therapeutic Area: Oncology Product Name: DB108
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Jiangsu Wuzhong Pharmaceutical Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 10, 2020
Details:
Denovo plans to conduct a randomized, double-blind, placebo-controlled Phase 3 pivotal study of enzastaurin in combination with temozolomide, both during and following radiation therapy, in newly-diagnosed glioblastoma patients.
Lead Product(s): Enzastaurin,Temozolomide
Therapeutic Area: Oncology Product Name: Kinenza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2020
Details:
The acquisition includes Tocagen's retroviral replicating vector platform, investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC and several other development programs.
Lead Product(s): Vocimagene amiretrorepvec
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Forte Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
